Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center
Articles by Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center

Role of Rebiopsy in R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute The rationale for rebiopsying patients who have relapsed/refractory follicular lymphoma and the types of molecular information that can be applied to treatment decisions.

R/R Follicular Lymphoma: Second-line Treatment Selection
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Factors that hematologist-oncologists need to consider when selecting second-line therapy for relapsed follicular lymphoma.

R/R Follicular Lymphoma: Patient Prognosis
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Insight regarding the prognosis for patients with follicular lymphoma who relapse and impact of treatment sequencing on this trajectory.